Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Mindfulness in migraine.

Wells RE, Seng EK, Edwards RR, Victorson DE, Pierce CR, Rosenberg L, Napadow V, Schuman-Olivier Z.

Expert Rev Neurother. 2020 Jan 14. doi: 10.1080/14737175.2020.1715212. [Epub ahead of print]

PMID:
31933391
2.

A Change Management Case Study for Safe Opioid Prescribing and Opioid Use Disorder Treatment.

Sokol R, Schuman-Olivier Z, Batalden M, Sullivan L, Shaughnessy AF.

J Am Board Fam Med. 2020 Jan-Feb;33(1):129-137. doi: 10.3122/jabfm.2020.01.190223.

3.

Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation.

Sokol R, Albanese M, Chew A, Early J, Grossman E, Roll D, Sawin G, Wu DJ, Schuman-Olivier Z.

Addict Sci Clin Pract. 2019 Dec 27;14(1):47. doi: 10.1186/s13722-019-0176-y.

4.

Implementing group visits for opioid use disorder: A case series.

Sokol R, Albanese M, Albanese C, Coste G, Grossman E, Morrill D, Roll D, Sobieszczyk A, Schuman-Olivier Z.

Subst Abus. 2019 Aug 16:1-7. doi: 10.1080/08897077.2019.1635958. [Epub ahead of print]

PMID:
31418638
5.

Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review.

Steinkamp JM, Goldblatt N, Borodovsky JT, LaVertu A, Kronish IM, Marsch LA, Schuman-Olivier Z.

JMIR Ment Health. 2019 Mar 12;6(3):e12493. doi: 10.2196/12493.

6.

Mindfulness Training Enhances Self-Regulation and Facilitates Health Behavior Change for Primary Care Patients: a Randomized Controlled Trial.

Gawande R, To MN, Pine E, Griswold T, Creedon TB, Brunel A, Lozada A, Loucks EB, Schuman-Olivier Z.

J Gen Intern Med. 2019 Feb;34(2):293-302. doi: 10.1007/s11606-018-4739-5. Epub 2018 Dec 3.

PMID:
30511291
7.

MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.

Schuman-Olivier Z, Borodovsky JT, Steinkamp J, Munir Q, Butler K, Greene MA, Goldblatt J, Xie HY, Marsch LA.

Addict Sci Clin Pract. 2018 Sep 24;13(1):21. doi: 10.1186/s13722-018-0122-4.

8.

Interoception in Psychiatric Disorders: A Review of Randomized, Controlled Trials with Interoception-Based Interventions.

Khoury NM, Lutz J, Schuman-Olivier Z.

Harv Rev Psychiatry. 2018 Sep/Oct;26(5):250-263. doi: 10.1097/HRP.0000000000000170. Review.

9.

Mindfulness-based cognitive therapy for bipolar disorder: A systematic review.

Lovas DA, Schuman-Olivier Z.

J Affect Disord. 2018 Nov;240:247-261. doi: 10.1016/j.jad.2018.06.017. Epub 2018 Jul 6.

PMID:
30086469
10.

Group-based treatment of opioid use disorder with buprenorphine: A systematic review.

Sokol R, LaVertu AE, Morrill D, Albanese C, Schuman-Olivier Z.

J Subst Abuse Treat. 2018 Jan;84:78-87. doi: 10.1016/j.jsat.2017.11.003. Epub 2017 Nov 9. Review.

PMID:
29195596
11.

Why use group visits for opioid use disorder treatment in primary care? A patient-centered qualitative study.

Sokol R, Albanese C, Chaponis D, Early J, Maxted G, Morrill D, Poirier G, Puopolo F, Schuman-Olivier Z.

Subst Abus. 2018 Jan 2;39(1):52-58. doi: 10.1080/08897077.2017.1356792. Epub 2017 Sep 8.

PMID:
28723302
12.

Meditation and Medication-What About a Middle Path?

Lovas DA, Lutz J, Schuman-Olivier Z.

JAMA Psychiatry. 2016 Dec 1;73(12):1294-1295. doi: 10.1001/jamapsychiatry.2016.1471. No abstract available.

PMID:
27784039
13.

Mindfulness and Cardiovascular Disease Risk: State of the Evidence, Plausible Mechanisms, and Theoretical Framework.

Loucks EB, Schuman-Olivier Z, Britton WB, Fresco DM, Desbordes G, Brewer JA, Fulwiler C.

Curr Cardiol Rep. 2015 Dec;17(12):112. doi: 10.1007/s11886-015-0668-7. Review.

14.

Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.

Schuman-Olivier Z, Claire Greene M, Bergman BG, Kelly JF.

Drug Alcohol Depend. 2014 Nov 1;144:178-85. doi: 10.1016/j.drugalcdep.2014.09.009. Epub 2014 Sep 18.

15.

Emerging adult age status predicts poor buprenorphine treatment retention.

Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ.

J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. Epub 2014 May 20.

16.

Finding the right match: mindfulness training may potentiate the therapeutic effect of nonjudgment of inner experience on smoking cessation.

Schuman-Olivier Z, Hoeppner BB, Evins AE, Brewer JA.

Subst Use Misuse. 2014 Apr;49(5):586-94. doi: 10.3109/10826084.2014.850254.

17.

Clinician beliefs and attitudes about buprenorphine/naloxone diversion.

Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA Jr, Weiss RD.

Am J Addict. 2013 Nov-Dec;22(6):574-80. doi: 10.1111/j.1521-0391.2013.12024.x. Epub 2013 Apr 11.

18.

Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ.

Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. Epub 2013 May 18.

19.

How Does Mindfulness Meditation Work? Proposing Mechanisms of Action From a Conceptual and Neural Perspective.

Hölzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U.

Perspect Psychol Sci. 2011 Nov;6(6):537-59. doi: 10.1177/1745691611419671.

PMID:
26168376
20.

Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers.

Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, Klinker L, Shaffer HJ.

J Subst Abuse Treat. 2010 Jul;39(1):41-50. doi: 10.1016/j.jsat.2010.03.014.

PMID:
20434868
21.

The use of palliative sedation for existential distress: a psychiatric perspective.

Schuman-Olivier Z, Brendel DH, Forstein M, Price BH.

Harv Rev Psychiatry. 2008;16(6):339-51. doi: 10.1080/10673220802576917. Review.

PMID:
19085388
22.

A preliminary study of spiritual self-schema (3-S(+)) therapy for reducing impulsivity in HIV-positive drug users.

Margolin A, Schuman-Olivier Z, Beitel M, Arnold RM, Fulwiler CE, Avants SK.

J Clin Psychol. 2007 Oct;63(10):979-99.

PMID:
17828761
23.

Psychometric properties of a Chinese version of the Psychological Mindedness Scale.

Hua W, Beitel M, Schuman-Olivier Z, Declan B.

J Am Psychoanal Assoc. 2007 Winter;55(1):300-5. No abstract available.

PMID:
17432509
24.

Reflections by inner-city drug users on a Buddhist-based spirituality-focused therapy: a qualitative study.

Beitel M, Genova M, Schuman-Olivier Z, Arnold R, Avants SK, Margolin A.

Am J Orthopsychiatry. 2007 Jan;77(1):1-9.

PMID:
17352579
25.

A controlled study of a spirituality-focused intervention for increasing motivation for HIV prevention among drug users.

Margolin A, Beitel M, Schuman-Olivier Z, Avants SK.

AIDS Educ Prev. 2006 Aug;18(4):311-22.

PMID:
16961448

Supplemental Content

Loading ...
Support Center